Drug-carrying nanoparticles shrink venous malformations by 70% in mice

edited by Swati Mestri , reviewed by Robert Egan

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:

Add as preferred source Venous malformations are abnormally shaped veins that develop when the cells lining blood vessels grow too fast when they aren't supposed to. Children can be born with them, and as the child grows, the venous malformations can get bigger. Venous malformations are a type of vascular malformation that can range from small and superficial to disfiguring, debilitating or even life-threatening.

Not satisfied with current treatments, critical care physicians Kathleen "Kate" Cullion, MD, Ph.D., and Daniel Kohane, MD, Ph.D., director of Boston Children's Laboratory for Biomaterials and Drug Delivery, wondered several years ago whether they could develop better treatments. Together with postdoctoral fellow Weimin Tang, Ph.D., they recently developed nanoparticles that deliver drug treatment directly to venous malformations to help shrink them.

The work is published in the journal Science Translational Medicine .

Venous malformations can affect how a person functions in day-to-day life and may impede vital functions, like breathing, swallowing and moving. According to the researchers, they can be very difficult to treat.

Large venous malformations can be too risky to remove surgically because of the danger of excessive blood loss. In these cases, patients take medications like rapamycin to block cell growth, which also helps prevent venous malformations from enlarging.

Taken regularly, these medications can cause side effects. As a result, some patients stop taking them, and the venous malformations continue to grow.

"Kate and I cared for a patient with a different type of vascular malformation who had a contrast dye study to get a better view of the vessels, and the dye was still in the malformation two months after the study," says Kohane. "The dye was made up of nanoparticles that usually are not retained in normal blood vessels. The fact that they were retained in this patient suggested that the abnormal vessels were leaky."

Because of this observation, the researchers wondered whether the same would be true for the vessels that make up venous malformations. If so, they thought drug-loaded nanoparticles might accumulate in vessels that cause venous malformations.

Nanoparticles are extremely small carriers that can be filled with drugs. Here, instead of making a nanoparticle from generic materials that do not have therapeutic effects, Tang, Kohane and Cullion hypothesized that they could create a specially engineered nanoparticle using a new form of rapamycin they developed.

"Instead of giving the medicine rapamycin as individual molecules, we linked many molecules of rapamycin together into a larger structure—almost like turning loose beads into a necklace," says Cullion. "We then bundled those structures together to make tiny spheres, the nanoparticles."

"Within the nanoparticles are small spaces—like gaps in a ball of tangled necklaces—where we can tuck in other drugs, allowing multiple therapies to be delivered together."—Cullion, MD

Tang designed the bundled rapamycin, made nanoparticles and also tucked in the drug ponatinib. He then injected nanoparticles into mouse models of venous malformations and compared them with mice given both medications orally. After 20 days, they saw the greatest effect with the bundled rapamycin nanoparticles with added ponatinib, which reduced the venous malformation size by 70% after a single injection.

"What makes these nanoparticles different is that the rapamycin itself is a material from which the nanoparticle is made," says Tang. "These nanoparticles have rapamycin-like activity without needing to release free molecules of rapamycin. This brand-new formulation could be repurposed for a number of other diseases, as well."

The team plans to monitor the nanoparticles longer to see whether they continue to shrink the venous malformations or whether another injection will be required to completely eliminate them.

Weimin Tang et al, Polymeric rapamycin nanoparticles encapsulating ponatinib cause regression of venous malformations in mice, Science Translational Medicine (2026). DOI: 10.1126/scitranslmed.aeb7597

Journal information: Science Translational Medicine

Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Indexed and credited by AIPROPX. Originating outlet: Phys.org. Open at source →